TG Therapeutics (NASDAQ:TGTX) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of TG Therapeutics (NASDAQ:TGTX) from a hold rating to a sell rating in a research report report published on Friday.

TGTX has been the subject of several other reports. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. TD Cowen started coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. Finally, JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Down 5.0 %

TGTX stock opened at $31.70 on Friday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a market capitalization of $4.93 billion, a price-to-earnings ratio of -316.97 and a beta of 2.24. The business has a 50 day simple moving average of $31.63 and a two-hundred day simple moving average of $26.59. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period last year, the company earned $0.73 EPS. Research analysts anticipate that TG Therapeutics will post 0.08 EPS for the current fiscal year.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of TG Therapeutics

Several hedge funds have recently modified their holdings of TGTX. State Street Corp raised its stake in shares of TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of TG Therapeutics by 0.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock worth $27,708,000 after purchasing an additional 7,939 shares in the last quarter. Principal Financial Group Inc. grew its stake in TG Therapeutics by 7.5% during the 4th quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company’s stock worth $24,989,000 after buying an additional 57,996 shares during the last quarter. JPMorgan Chase & Co. increased its position in TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares in the last quarter. Finally, Braun Stacey Associates Inc. acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $13,328,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.